Urolution Medical, Inc. appears in FDA premarket records as the applicant for a single traditional 510(k), K261141, covering a device named OpenFlo Urinary Catheter. The filing was received on April 7, 2026, and received a substantially equivalent decision on October 6, 2026, with the Gastroenterology/Urology advisory committee and product code EZL. The company’s own published pages describe a Minnesota-based device developer working on indwelling catheter design, and state that OpenFlo received FDA 510(k) clearance in October 2026. [1][2][4][8]

The applicant and the cleared device

FDA records identify Urolution Medical, Inc. as the applicant on K261141, a traditional 510(k) with a Summary, reviewed by the Gastroenterology/Urology panel and not reviewed by a third party. The device is listed as OpenFlo Urinary Catheter under product code EZL, with a substantially equivalent decision dated October 6, 2026. The same filing appears in FDA’s premarket notification listing with the same dates and decision code. [1][2][8]

The openFDA classification fields attached to K261141 describe the device category as Catheter, Retention Type, Balloon, class 2, regulation number 876.5130, with medical specialties listed as Gastroenterology and Urology. Those fields describe the regulatory category the clearance sits within; they are not a statement about the device’s clinical performance. [1]

How the company describes OpenFlo

Urolution’s published OpenFlo page describes the product as an indwelling urinary catheter designed to address challenges associated with traditional Foley catheters, and states that it recreates the body’s natural drainage mechanism for urine. The same page discusses the exposed tip and vertical drainage port positioned above the balloon on traditional catheters. These are the manufacturer’s own descriptions of design intent. [3]

The company’s About page frames OpenFlo as its first technology, developed by reconsidering how a catheter drains and interacts with the bladder, and states that Urolution has patented the OpenFlo technology and design, manufactured the device, and completed testing to support its 510(k) submission. The page gives an establishment year of 2022. A separate company page states that Urolution was co-founded in 2021 by Weihao Qu and describes involvement in design, manufacturing, and marketing of the OpenFlo catheter. [4][5]

A company About Us page states that the manufacturing facility is located in Maple Grove, Minnesota, at 10550 County Road 81 STE 219, and describes the company as founded by medical device veterans and clinical specialists. The FDA filing lists the same street address for the applicant. That address is a filing and facility address in the records; no separate corporate headquarters designation is documented. [1][6]

Filing scope and dated record

The K261141 record shows a date received of April 7, 2026, and a decision date of October 6, 2026, with decision code SESE and clearance type Traditional. The FDA premarket notification page for the same number lists the review panel as Gastroenterology/Urology, type Traditional, third-party review as No, combination product as No, and no authorized predetermined change control plan. [1][2]

In the collection linked as of November 20, 2026, the portfolio contains one linked record, a 510(k), and the decision counts show one SESE decision; the explicitly smaller record sample also contains one SESE entry, K261141. These counts describe the linked filing set at that date and are not measures of sales, total portfolio, or safety performance. [1]

Stated next steps

Urolution’s About page states that the company is preparing clinical studies to evaluate comparative catheter performance and patient outcomes, and is pursuing strategic partnerships, additional capital, and commercial relationships with established healthcare organizations as OpenFlo moves toward broader market introduction. Those are company statements about planned activity; no study results or commercial availability are documented in the linked records. [4]

An earlier version of the company’s OpenFlo page carries a note stating that the product is not yet FDA approved, alongside a 2025 copyright line. The FDA record dated October 6, 2026, shows a substantially equivalent 510(k) decision for K261141. The two statements come from different publishers and dates, and the current commercial status of the device is not otherwise documented. [1][3]